A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy

A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African I-BRD9 site Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Reduced threat Later age of onset No risk association No risk association No threat association Decreased risk of eR+ BC No IKK 16 supplier danger association increased overall threat No danger association increased danger of eR- BC enhanced risk improved risk No threat association enhanced risk No risk association increased threat No risk association increased danger No risk association improved danger No danger association Decreased threat No threat association increased general danger No threat association No threat association enhanced general threat No risk association Decreased danger of eR+ BC enhanced threat of eR- BC No danger association Decreased risk No risk association elevated risk of eR+ No danger association No risk association Decreased threat of eR- BC Decreased risk of eR+ BC No threat association Decreased threat of eR+ No threat association No risk association elevated general risk Decreased all round threat No threat association No danger association increased risk of eR- BC improved risk elevated danger improved risk elevated risk in eR+ earlier age of onset enhanced danger (A allele) earlier age of onset (C allele) Decreased threat Decreased threat elevated threat Reduced survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 3 UTR BMPR1B 3 UTR BRCA1 three UTR HPGD 3 UTR IGF-1R 3 UTR IL23R 3 UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 three UTR ITGB4 three UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable two (Continued)miRNA locus KRAS 3 UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation enhanced frequency in BRCA1 carriers/no threat association improved threat of TNBC Decreased risk elevated threat and poor survival earlier age of onset improved threat elevated risk Decreased threat Decreased all round danger No threat association Decreased threat of eR+ BC No risk association increas.A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Lowered threat Later age of onset No risk association No danger association No risk association Decreased danger of eR+ BC No risk association elevated all round danger No threat association improved threat of eR- BC improved risk improved threat No risk association enhanced risk No danger association enhanced threat No threat association increased danger No danger association increased risk No threat association Decreased threat No risk association elevated overall threat No threat association No threat association improved all round danger No danger association Decreased threat of eR+ BC increased danger of eR- BC No danger association Decreased threat No threat association improved danger of eR+ No risk association No danger association Decreased risk of eR- BC Decreased risk of eR+ BC No threat association Decreased danger of eR+ No threat association No threat association improved all round risk Decreased all round threat No danger association No danger association increased risk of eR- BC elevated threat elevated threat elevated threat enhanced threat in eR+ earlier age of onset improved danger (A allele) earlier age of onset (C allele) Decreased threat Decreased threat elevated risk Reduced survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 3 UTR BMPR1B 3 UTR BRCA1 3 UTR HPGD three UTR IGF-1R three UTR IL23R 3 UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 3 UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable two (Continued)miRNA locus KRAS three UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation increased frequency in BRCA1 carriers/no danger association increased risk of TNBC Decreased danger improved danger and poor survival earlier age of onset increased risk increased threat Decreased risk Decreased all round danger No threat association Decreased danger of eR+ BC No threat association increas.